CLLS Cellectis S.A. IFRS
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1627281 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 · USD | FY20242024-12-31 · USD | FY20232023-12-31 · USD | FY20222022-12-31 · USD | FY20212021-12-31 · USD |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $72.95M | $41.51M | $755,000 | $19.17M | $30.35M |
| Cost of revenue | $0 | $0 | $737,000 | $1.77M | $1.84M |
| Gross profit | $72.95M | $41.51M | $18,000 | $17.40M | $28.50M |
| R&D expense | $93.52M | $90.54M | $87.65M | $97.50M | $117.84M |
| SG&A expense | $19.79M | $19.09M | $16.81M | $17.49M | $22.88M |
| Operating income | -$33.08M | -$59.55M | -$97.30M | -$89.67M | -$103.48M |
| Interest expense | $51.06M | $21.61M | $40.64M | $17.82M | $6.49M |
| Pretax income | -$68.02M | -$36.76M | -$116.46M | -$98.60M | -$96.75M |
| Income tax | -$423,000 | $0 | $371,000 | $87,000 | $0 |
| Net income | -$67.59M | -$36.76M | -$101.06M | -$106.14M | -$114.20M |
| EBITDA | -$13.01M | -$39.71M | -$78.78M | -$71.23M | -$89.33M |
| EPS (basic) | -0.67 | -0.41 | -1.77 | -2.33 | -2.55 |
| EPS (diluted) | -0.67 | -0.41 | -1.77 | -2.33 | -2.55 |
| Weighted avg. shares (diluted) | 100.28M | 90.57M | 57.01M | 45.55M | 44.82M |
| Balance sheet | |||||
| Cash & equivalents | $61.53M | $143.25M | $136.71M | $93.22M | $185.64M |
| Short-term investments | $144.80M | $115.80M | — | — | — |
| Receivables | $14.40M | $6.71M | $569,000 | $772,000 | $20.36M |
| Inventory | — | — | — | $0 | $0 |
| Current assets | — | — | — | $122.04M | $225.43M |
| PP&E, netmay include right-of-use assets (IFRS) | $38.79M | $45.90M | $54.68M | $63.62M | $78.85M |
| Intangibles | $535,000 | $1.12M | — | — | — |
| Total assets | $324.72M | $383.54M | $334.27M | $261.22M | $382.08M |
| Current liabilities | $145.75M | $166.27M | $155.14M | $48.13M | $49.35M |
| Total liabilities | $248.82M | $252.51M | $249.57M | $135.28M | $145.60M |
| Shareholders' equity | $75.90M | $131.03M | $84.69M | $117.97M | $221.29M |
| Shares outstanding | 100.34M | 100.09M | 71.75M | 45.68M | 45.48M |
| Cash flow statement | |||||
| Operating cash flow | -$39.40M | $22.99M | -$24.75M | -$87.44M | -$104.56M |
| Capital expenditure | $2.36M | $2.58M | $1.07M | $2.43M | $18.54M |
| Free cash flow | -$41.76M | $20.41M | -$25.82M | -$89.88M | -$123.11M |
| Investing cash flow | -$29.48M | -$102.81M | -$15.51M | -$2.76M | $7.28M |
| Financing cash flow | -$16.76M | $89.11M | $82.86M | $1.15M | $47.52M |
| Depreciation & amortization | $20.06M | $19.85M | $18.52M | $18.43M | $14.16M |
| Stock-based compensation | $6.11M | $3.17M | $5.23M | $6.04M | $11.49M |
Free plan shows the latest 5 periods; Pro shows all 12 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company uses different currencies across periods or line items (e.g. USD convenience translations in annual reports). Each column header shows its currency and cells in a different currency are marked; do not compare figures across currencies. Charts use only periods in the latest period's currency.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.